Regulatory mechanisms for malignant properties of cancer cells with disialyl and monosialyl gangliosides

Glycosignals in Cancer: Mechanisms of Malignant Phenotypes

Volumn , Issue , 2016, Pages 57-76

  Furukawa, Koichi ^a,b   Ohkawa, Yuki ^a,b   Furukawa, Keiko ^a,b   Matsumoto, Yasuyuki ^a   Ohmi, Yuhsuke ^a   Hashimoto, Noboru ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUBU UNIVERSITY   (Japan)

Author keywords

Cancer associated antigen; Ganglioside; Glycosyltransferase; Integrin; Lipid rafts; Melanoma; Metastasis

Indexed keywords

EID: 84960489314     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-4-431-55939-9_4     Document Type: Chapter

References (119)

1. Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S, Ueda R (2005) Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J Biol Chem 280:29828–29836
2. Aksoy N, Akinci OF (2004) Mucin macromolecules in normal, adenomatous, and carcinomatous colon: evidence for the neotransformation. Macromol Biosci 4:483–496
3. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M (2012) Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122:2066–2078
4. Blackhall FH, Shepherd FA (2007) Small cell lung cancer and targeted therapies. Curr Opin Oncol 19:103–108
5. Brockhausen I (1999) Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta 1473:67–95
6. Brooks SA, Carter TM, Bennett EP, Clausen H, Mandel U (2007) Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer. Acta Histochem 109:273–284
7. Brown DA, London E (1998) Structure and origin of ordered lipid domains in biological membranes. J Membr Biol 164:103–114
8. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, Defilippi P (2010) Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 10:858–870
9. Carubia JM, Yu RK, Macala LJ, Kirkwood JM, Varga JM (1984) Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun 120:500–504
10. Castel V, Segura V, Canete A (2010) Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clin Transl Oncol 12:788–793
11. Cazet A, Lefebvre J, Adriaenssens E, Julien S, Bobowski M, Grigoriadis A, Tutt A, Tulasne D, Le Bourhis X, Delannoy P (2010) GD3 synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res 8:1526–1535
12. Chen HH, Fukumoto S, Furukawa K, Nakao A, Akiyama S, Urano T (2003) Suppression of lung metastasis of mouse Lewis lung cancer P29 with transfection of the ganglioside GM2/GD2 synthase gene. Int J Cancer 103:169–176
13. Cheresh DA, Rosenberg J, Mujoo K, Hirschowitz L, Reisfeld RA (1986) Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res 46:5112–5118
14. Dall’Olio F, Malagolini N, Trinchera M, Chiricolo M (2012) Mechanisms of cancer-associated glycosylation changes. Front Biosci (Landmark Ed) 17:670–99
15. Daniotti JL, Vilcaes AA, Torres Demichelis V, Ruggiero FM, Rodriguez-Walker M (2013) Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. Front Oncol 3:306
16. Dong Y, Ikeda K, Hamamura K, Zhang Q, Kondo Y, Matsumoto Y, Ohmi Y, Yamauchi Y, Furukawa K, Taguchi R (2010) GM1 /GD1b /GA1 synthase expression results in the reduced cancer phenotypes with modulation of composition and raft-localization of gangliosides in a melanoma cell line. Cancer Sci 101:2039–2047
17. Durrant LG, Noble P, Spendlove I (2012) Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol 167:206–215
18. Ferrari G, Anderson BL, Stephens RM, Kaplan DR, Greene LA (1995) Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors. J Biol Chem 270:3074–3080
19. Fishman PH, Brady RO (1976) Biosynthesis and function of gangliosides. Science 194:906–915
20. Fredman P, von Holst H, Collins VP, Ammar A, Dellheden B, Wahren B, Granholm L, Svennerholm L (1986) Potential ganglioside antigens associated with human gliomas. Neurol Res 8:123–126
21. Fukuda M, Horibe K, Furukawa K (1998) Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220–51 against human neuroblastoma by granulocytemacrophage colony-stimulating factor and granulocyte colony-stimulating factor. Int J Mol Med 2:471–475
22. Fukumoto S, Mutoh T, Hasegawa T, Miyazaki H, Okada M, Goto G, Furukawa K, Urano T (2000) GD3 synthase gene expression in PC12 cells results in the continuous activation of TrkA and ERK1/2 and enhanced proliferation. J Biol Chem 275:5832–5838
23. Furukawa K, Hamamura K, Aixinjueluo W (2006) Biosignals modulated by tumor-associated carbohydrate antigens: novel targets for cancer therapy. Ann N Y Acad Sci 1086:185–198
24. Furukawa K, Hamamura K, Nakashima H (2008) Molecules in the signaling pathway activated by gangliosides can be targets of therapeutics for malignant melanomas. Proteomics 8:3312–3316
25. Furukawa K, Hamamura K, Ohkawa Y, Ohmi Y (2012a) Disialyl gangliosides enhance tumor phenotypes with differential modalities. Glycoconj J 29:579–584
26. Furukawa K, Ohkawa Y, Yamauchi Y, Hamamura K, Ohmi Y (2012b) Fine tuning of cell signals by glycosylation. J Biochem 151:573–578
27. Furukawa K, Kambe M, Miyata M, Ohkawa Y, Tajima O (2014) Ganglioside GD3 induces convergence and synergism of adhesion and hepatocyte growth factor/Met signals in melanomas. Cancer Sci 105:52–63
28. Furukawa K, Lloyd KO (1990) Gangliosides in melanoma. In: Ferrone S (ed) Human melanoma: from basic research to clinical application. Springer, Heidelberg, pp 15–30
29. Furukawa K, Akagi T, Nagata Y, Yamada Y, Shimotohno K, Cheung NK, Shiku H (1993) GD2 ganglioside on human T-lymphotropic virus type I-infected T cells: possible activation of beta- 1,4-N-acetylgalactosaminyltransferase gene by p40tax. Proc Natl Acad Sci USA 90:1972–1976
30. Grant SC, Kostakoglu L, Kris MG, Yeh SD, Larson SM, Finn RD, Oettgen HF, Cheung NV (1996) Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur J Nucl Med 23:145–149
31. Greene LA, Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73:2424–2428
32. Hakomori S (1985) Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 45:2405–2414
33. Hakomori S, Yamamura S, Handa AK (1998) Signal transduction through glyco- (sphingo)lipids. Introduction and recent studies on glyco(sphingo)lipid-enriched microdomains. Ann N Y Acad Sci 845:1–10
34. Hakomori S (2002a) Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 99:10231–10233
35. Hakomori SI (2002b) The glycosynapse. Proc Natl Acad Sci USA 99:225–232
36. Hakomori S, Handa K (2002) Glycosphingolipid-dependent cross-talk between glycosynapses interfacing tumor cells with their host cells: essential basis to define tumor malignancy. FEBS Lett 531:88–92
37. Hakomori SI (2010) Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility. FEBS Lett 584:1901–1906
38. Hamamura K, Tsuji M, Ohkawa Y, Nakashima H, Miyazaki S, Urano T, Yamamoto N, Ueda M, Furukawa K (2008) Focal adhesion kinase as well as p130Cas and paxillin is crucially involved in the enhanced malignant properties under expression of ganglioside GD3 in melanoma cells. Biochim Biophys Acta 1780:513–519
39. Hamamura K, Furukawa K, Hayashi T, Hattori T, Nakano J, Nakashima H, Okuda T, Mizutani H, Hattori H, Ueda M, Urano T, Lloyd KO (2005) Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acad Sci USA 102:11041–11046
40. Hamamura K, Tsuji M, Hotta H, Ohkawa Y, Takahashi M, Shibuya H, Nakashima H, Yamauchi Y, Hashimoto N, Hattori H, Ueda M, Furukawa K (2011) Functional activation of Src family kinase yes protein is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. J Biol Chem 286:18526–18537
41. Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Sone S (1996) Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes. Jpn J Cancer Res 87:497–504
42. Haraguchi M, Yamashiro S, Yamamoto A, Furukawa K, Takamiya K, Lloyd KO, Shiku H (1994) Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc Natl Acad Sci USA 91:10455–10459
43. Hashimoto N, Hamamura K, Kotani N, Furukawa K, Kaneko K, Honke K, Furukawa K (2012) Proteomic analysis of ganglioside-associated membrane molecules: substantial basis for molecular clustering. Proteomics 12:3154–3163
44. Heiner JP, Miraldi F, Kallick S, Makley J, Neely J, Smith-Mensah WH, Cheung NK (1987) Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res 47:5377–5381
45. Hersey P (1991) Ganglioside antigens in tissue sections of skin, naevi, and melanoma-- implications for treatment of melanoma. Cancer Treat Res 54:137–151
46. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4:45–60
47. Irie RF, Morton DL (1986) Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83:8694–8698
48. Irie RF, Matsuki T, Morton DL (1989) Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1:786–787
49. Ju T, Otto VI, Cummings RD (2011) The Tn antigen-structural simplicity and biological complexity. Angew Chem Int Ed Engl 50:1770–1791
50. Ju T, Wang Y, Aryal RP, Lehoux SD, Ding X, Kudelka MR, Cutler C, Zeng J, Wang J, Sun X, Heimburg-Molinaro J, Smith DF, Cummings RD (2013) Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers. Proteomics Clin Appl 7:618–631
51. Kannagi R, Yin J, Miyazaki K, Izawa M (2008) Current relevance of incomplete synthesis and neo-synthesis for cancer associated alteration of carbohydrate determinants--Hakomori’s concepts revisited. Biochim Biophys Acta 1780:525–531
52. Kaucic K, Liu Y, Ladisch S (2006) Modulation of growth factor signaling by gangliosides: positive or negativę Methods Enzymol 417:168–185
53. Ko K, Furukawa K, Takahashi T, Urano T, Sanai Y, Nagino Y, Nimura Y, Furukawa K (2006) Fundamental study of small interfering RNAs for ganglioside GD3 synthase as a therapeutic target of lung cancers. Oncogene 25:6924–6935
54. Kotani N, Gu J, Isaji T, Udaka K, Taniguchi N, Honke K (2008) Biochemical visualization of cell surface molecular clustering in living cells. Proc Natl Acad Sci USA 105:7405–7409
55. Kusumi A, Fujiwara TK, Morone N, Yoshida KJ, Chadda R, Xie M, Kasai RS, Suzuki KG (2012) Membrane mechanisms for signal transduction: the coupling of the meso-scale raft domains to membrane-skeleton-induced compartments and dynamic protein complexes. Semin Cell Dev Biol 23:126–144
56. Lloyd KO, Old LJ (1989) Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. Cancer Res 49:3445–3451
57. Lopez PH, Schnaar RL (2009) Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol 19:549–557
58. Malisan F, Testi R (2002) GD3 ganglioside and apoptosis. Biochim Biophys Acta 1585:179–187
59. Margadant C, Monsuur HN, Norman JC, Sonnenberg A (2011) Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol 23:607–614
60. Matsumoto Y, Zhang Q, Akita K, Nakada H, Hamamura K, Tsuchida A, Okajima T, Furukawa K, Urano T (2013) Trimeric Tn antigen on syndecan 1 produced by ppGalNAc-T13 enhances cancer metastasis via a complex formation with integrin a5ß1 and matrix metalloproteinase 9. J Biol Chem 288:24264–24276
61. Matsumoto Y, Zhang Q, Akita K, Nakada H, Hamamura K, Tokuda N, Tsuchida A, Matsubara T, Hori T, Okajima T, Furukawa K, Urano T (2012) pp-GalNAc-T13 induces high metastatic potential of murine Lewis lung cancer by generating trimeric Tn antigen. Biochem Biophys Res Commun 419:7–13
62. Matsumoto-Takasaki A, Hanashima S, Aoki A, Yuasa N, Ogawa H, Sato R, Kawakami H, Mizuno M, Nakada H, Yamaguchi Y, Fujita-Yamaguchi Y (2012) Surface plasmon resonance and NMR analyses of anti Tn-antigen MLS128 monoclonal antibody binding to two or three consecutive Tn-antigen clusters. J Biochem 151:273–282
63. Matthay KK, George RE, Yu AL (2012) Promising therapeutic targets in neuroblastoma. Clin Cancer Res 18:2740–2753
64. Meng X, Zhong J, Liu S, Murray M, Gonzalez-Angulo AM (2012) A new hypothesis for the cancer mechanism. Cancer Metastasis Rev 31:247–268
65. Merritt WD, Casper JT, Lauer SJ, Reaman GH (1987) Expression of GD3 ganglioside in childhood T-cell lymphoblastic malignancies. Cancer Res 47:1724–1730
66. Mitsuda T, Furukawa K, Fukumoto S, Miyazaki H, Urano T (2002) Overexpression of ganglioside GM1 results in the dispersion of platelet-derived growth factor receptor from glycolipidenriched microdomains and in the suppression of cell growth signals. J Biol Chem 277:11239–11246
67. Miyata M, Ichihara M, Tajima O, Sobue S, Kambe M, Sugiura K, Furukawa K (2014) UVB-irradiated keratinocytes induce melanoma-associated ganglioside GD3 synthase gene in melanocytes via secretion of tumor necrosis factor a and interleukin 6. Biochem Biophys Res Commun 445:504–510
68. Miyazaki H, Fukumoto S, Okada M, Hasegawa T, Furukawa K (1997) Expression cloning of rat cDNA encoding UDP-galactose: GD2 beta 1,3-galactosyltransferase that determines the expression of GD1b/GM1/GA1. J Biol Chem 272:24794–24799
69. Morita N, Yajima Y, Asanuma H, Nakada H, Fujita-Yamaguchi Y (2009) Inhibition of cancer cell growth by anti-Tn monoclonal antibody MLS128. Biosci Trends 3:32–37
70. Munesue S, Kusano Y, Oguri K, Itano N, Yoshitomi Y, Nakanishi H, Yamashina I, Okayama M (2002) The role of syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-derived metastatic clones. Biochem J 363:201–209
71. Munesue S, Yoshitomi Y, Kusano Y, Koyama Y, Nishiyama A, Nakanishi H, Miyazaki K, Ishimaru T, Miyaura S, Okayama M, Oguri K (2007) A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 282:28164–28174
72. Munro S (2003) Lipid rafts: elusive or illusivę Cell 115:377–388
73. Mutoh T, Tokuda A, Miyadai T, Hamaguchi M, Fujiki N (1995) Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc Natl Acad Sci USA 92:5087–5091
74. Nagai Y (1995) Functional roles of gangliosides in bio-signaling. Behav Brain Res 66:99–104
75. Nakashima H, Hamamura K, Houjou T, Taguchi R, Yamamoto N, Mitsudo K, Tohnai I, Ueda M, Urano T, Furukawa K (2007) Overexpression of caveolin-1 in a human melanoma cell line results in dispersion of ganglioside GD3 from lipid rafts and alteration of leading edges, leading to attenuation of malignant properties. Cancer Sci 98:512–520
76. Nishio M, Fukumoto S, Furukawa K, Ichimura A, Miyazaki H, Kusunoki S, Urano T (2004) Overexpressed GM1 suppresses nerve growth factor (NGF) signals by modulating the intracellular localization of NGF receptors and membrane fluidity in PC12 cells. J Biol Chem 279:33368–33378
77. Ohkawa Y, Miyazaki S, Miyata M, Hamamura K, Furukawa K (2008) Essential roles of integrinmediated signaling for the enhancement of malignant properties of melanomas based on the expression of GD3. Biochem Biophys Res Commun 373:14–19
78. Ohkawa Y, Miyazaki S, Hamamura K, Kambe M, Miyata M, Tajima O, Ohmi Y, Yamauchi Y, Furukawa K (2010) Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains. J Biol Chem 285:27213–27223
79. Okada M, Furukawa K, Yamashiro S, Yamada Y, Haraguchi M, Horibe K, Kato K, Tsuji Y (1996) High expression of ganglioside alpha-2,8-sialyltransferase (GD3 synthase) gene in adult T-cell leukemia cells unrelated to the gene expression of human T-lymphotropic virus type I. Cancer Res 56:2844–2848
80. Old LJ (1981) Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res 41:361–375
81. Parsons K, Bernhardt B, Strickland B (2013) Targeted immunotherapy for high-risk neuroblastoma-- the role of monoclonal antibodies. Ann Pharmacother 47:210–218
82. Patra SK (2008) Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 1785:182–206
83. Peinado H et al (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18:883–891
84. Portoukalian J, Zwingelstein G, Doré JF (1979) Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 94:19–23
85. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ (1982) GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med 155:1133–1147
86. Quann K, Gonzales DM, Mercier I, Wang C, Sotgia F, Pestell RG, Lisanti MP, Jasmin JF (2013) Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide. Cell Cycle 12:1510–1520
87. Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG (2003) Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett 197:205–209
88. Ravindranath MH, Tsuchida T, Morton DL, Irie RF (1991) Ganglioside GM3: GD3 ratio as an index for the management of melanoma. Cancer 67:3029–3035
89. Razani B, Schlegel A, Liu J, Lisanti MP (2001) Caveolin-1, a putative tumour suppressor gene. Biochem Soc Trans 29:494–499
90. Rodeck U, Herlyn M (1988) Characteristics of cultured human melanocytes from different stages of tumor progression. Cancer Treat Res 43:3–16
91. Saito M, Yu RK, Cheung NK (1985) Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem Biophys Res Commun 127:1–7
92. Schengrund CL, Shochat SJ (1988) Gangliosides in neuroblastomas. Neurochem Pathol 8:189–202
93. Shibuya H, Hamamura K, Hotta H, Matsumoto Y, Nishida Y, Hattori H, Furukawa K, Ueda M (2012) Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci 103:1656–1664
94. Siddiqui B, Buehler J, DeGregorio MW, Macher BA (1984) Differential expression of ganglioside GD3 by human leukocytes and leukemia cells. Cancer Res 44:5262–5265
95. Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387:569–572
96. Simons K, Gerl MJ (2010) Revitalizing membrane rafts: new tools and insights. Nat Rev Mol Cell Biol 11:688–699
97. Simons K, Toomre D (2000) Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1:31–39
98. Suzuki KG, Kasai RS, Hirosawa KM, Nemoto YL, Ishibashi M, Miwa Y, Fujiwara TK, Kusumi A (2012) Transient GPI-anchored protein homodimers are units for raft organization and function. Nat Chem Biol 8:774–783
99. Suzuki KG, Kasai RS, Fujiwara TK, Kusumi A (2013) Single-molecule imaging of receptorreceptor interactions. Methods Cell Biol 117:373–390
100. Takenaga K (1986) Modification of the metastatic potential of tumor cells by drugs. Cancer Metastasis Rev 5:67–75
101. Thurin J, Thurin M, Herlyn M, Elder DE, Steplewski Z, Clark WH, Koprowski H (1986) GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lett 208:17–22
102. Vaudry D, Stork PJ, Lazarovici P, Eiden LE (2002) Signaling pathways for PC12 cell differentiation: making the right connections. Science 296:1648–1649
103. Welte K, Miller G, Chapman PB, Yuasa H, Natoli E, Kunicka JE, Cordon-Cardo C, Buhrer C, Old LJ, Houghton AN (1987) Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol 139:1763–1771
104. Wikstrand CJ, Fredman P, Svennerholm L, Bigner DD (1994) Detection of glioma- associated gangliosides GM2, GD2, GD3, 30-isoLM1 30,60-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. Prog Brain Res 101:213–223
105. Williams TM, Lisanti MP (2005) Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288:C494–506
106. Yamaguchi H, Furukawa K, Fortunato SR, Livingston PO, Lloyd KO, Oettgen HF, Old LJ (1987) Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci USA 84:2416–2420
107. Yamaguchi H, Furukawa K, Fortunato SR, Livingston PO, Lloyd KO, Oettgen HF, Old LJ (1990) Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient. Proc Natl Acad Sci USA 87:3333–3337
108. Yamashiro S, Okada M, Haraguchi M, Furukawa K, Lloyd KO, Shiku H (1995) Expression of alpha 2,8-sialyltransferase (GD3 synthase) gene in human cancer cell lines: high level expression in melanomas and up-regulation in activated T lymphocytes. Glycoconj J 12:894–900
109. Yanagisawa M, Taga T, Nakamura K, Ariga T, Yu RK (2005) Characterization of glycoconjugate antigens in mouse embryonic neural precursor cells. J Neurochem 95:1311–1320
110. Yates AJ (1988) Glycolipids and gliomas. Neurochem Pathol 8:157–180
111. Yates AJ, Saqr HE, Van Brocklyn J (1995) Ganglioside modulation of the PDGF receptor. A model for ganglioside functions. J Neurooncol 24:65–73
112. Yilmaz YE, Lawless JF, Andrulis IL, Bull SB (2013) Insights from mixture cure modeling of molecular markers for prognosis in breast cancer. J Clin Oncol 31:2047–2054
113. Yoon SJ, Nakayama K, Hikita T, Handa K, Hakomori SI (2005) Epidermal growth factor receptor tyrosine kinase is modulated by GM3 interaction with N-linked GlcNAc termini of the receptor. Proc Natl Acad Sci USA 103:18987–18991
114. Yoshida S, Kawaguchi H, Sato S, Ueda R, Furukawa K (2002) An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn J Cancer Res 93:816–824
115. Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda R, Furukawa K (2001) Ganglioside G(D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res 61:4244–4252
116. Zhan J, Han Q, Wang K (2013) Development of antibody therapeutics for small cell lung cancer. Expert Opin Investig Drugs 22:235–244
117. Zhang Q, Furukawa K, Chen HH, Sakakibara T, Urano T (2006) Metastatic potential of mouse Lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix metalloprotease-9 localization in lipid rafts. J Biol Chem 281:18145–18155
118. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer 73:42–49
119. Zhang Y, Iwasaki H, Wang H, Kudo T, Kalka TB, Hennet T, Kubota T, Cheng L, Inaba N, Gotoh M, Togayachi A, Guo J, Hisatomi H, Nakajima K, Nishihara S, Nakamura M, Marth JD, Narimatsu H (2003) Cloning and characterization of a new human UDP-N-acetyl-alpha-Dgalactosamine: polypeptide N-acetylgalactosaminyltransferase, designated pp-GalNAc-T13, that is specifically expressed in neurons and synthesizes GalNAc alpha-serine/threonine antigen. J Biol Chem 278:573–584